BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA Versus IMBRUVICA in Late-Breaking Oral Session at ASH 2022
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented